Search
Arotinolol
go.drugbank.com/drugs/DB09204InvestigationalArotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.
Migalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalFabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). … unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients.
Categories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological ChaperonesPropantheline
go.drugbank.com/drugs/DB00782ApprovedA muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
P2Y purinoceptor 12
go.drugbank.com/bio_entities/BE0000110TargetHumansReceptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation
Synonyms: ADP-glucose receptor, P2Y12 platelet ADP receptorFunction: G protein-coupled adenosine receptor activityGrowth arrest-specific protein 6
go.drugbank.com/bio_entities/BE0010201TargetHumansLigand for tyrosine-protein kinase receptors AXL, TYRO3 and MER whose signaling is implicated in cell growth and survival, cell adhesion and cell migration. GAS6/AXL signaling plays a role in various processes such as endothelial cell su...
Synonyms: AXL receptor tyrosine kinase ligandForeskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedTo construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. … A gel made of bovine collagen is used as the matrix for cell growth and differentiation.
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). … [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsPentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Corticorelin ovine triflutate
go.drugbank.com/drugs/DB09067ApprovedIt is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. … It provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ectopic ACTH syndrome (an ectopic source of ACTH excess).
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.